SenesTech, Inc. develops a technology for managing animal pest populations by controlling fertility. The company is headquartered in Phoenix, Arizona.
91 articles
SenesTech reported record Q2 revenue of $770,000 driven by Amazon sales of its rodent fertility control products, though negative cash flow highlights early-stage commercial challenges.
SenesTech Inc reported record Q2 2026 revenue of $770,000, a 56% increase driven by e-commerce and subscriptions. The company achieved a 76.60% gross margin despite a market capitalization of only $4.
SenesTech Inc. submitted a Form 4 filing to the SEC on September 30, disclosing insider trading activity or changes in beneficial ownership of securities.
SenesTech secured a new sales channel with Grove Collaborative for its Evolve rodent birth control products, driving Q2 revenue up 56.19% to USD 770,000 despite a net loss.
SenesTech Inc partners with Grove Collaborative to distribute Evolve® rodent birth control products online. The EPA-compliant solution utilizes naturally derived ingredients for sustainable pest manag
SenesTech announced its Evolve rodent birth control products will be available on Grove Collaborative's online marketplace, expanding distribution to sustainability-focused consumers. This strategic m
SenesTech partners with Grove Collaborative to distribute Evolve rodent birth control products via e-commerce. This move targets sustainability-focused consumers and expands market reach for the envir
SenesTech Inc. faces a lack of verified market catalysts for its stock, with analysts advising caution against confusing its ticker with Senseonics Holdings due to different market profiles.
SenesTech Inc. will virtually present at the Lytham Partners Fall 2026 Investor Conference on September 29-30, discussing its sustainable rodent population management products including Evolve® and Co
SenesTech CEO Michael Edell purchased 2,000 shares worth $1,740 as the stock trades near its 52-week low, amidst reports of record revenue but ongoing cash burn concerns.
SenesTech CEO Michael Edell discusses the company's unique rodent birth control niche and business model shifts toward e-commerce. He addresses recent stock underperformance, attributing it to early s
SenesTech CEO Michael Edell purchased 1,000 shares at $1.21 per share, increasing his direct ownership to 6,000 shares according to a Form 4 filing.
SenesTech Inc. announced it will present virtually at the Lytham Partners 2026 Consumer & Technology Investor Summit on August 18, highlighting its rodent birth control solutions like Evolve and Contr
SenesTech Inc reported a 2% overall revenue increase in Q1 2026 despite strong channel-specific growth, impacted by $443,000 in one-time operating expenses.
SenesTech Inc (SNES) holds an earnings forecast score of 8.00 within the Chemicals industry, with analysts projecting a $10.00 price target and negative EPS of -$0.41 for the next quarter.
Glenbrook Capital Management purchased 21,490 SenesTech shares at $1.297 per share, increasing its indirect holding to 1,079,294 shares without a Rule 10b5-1 plan.
SenesTech Inc is projected to report an earnings loss of 36 cents per share in its upcoming financial disclosure. This earnings preview aggregates expectations from sources such as Reuters via Trading
SenesTech Inc. reported Q2 2026 financial results with revenue increasing 23% year-over-year to $770K, driven primarily by its Evolve product. Despite a net loss of $1.83M, gross margins improved to 7
SenesTech reported narrower-than-expected losses and record revenue for Q2 2026, driven by strong e-commerce performance. Despite positive financial metrics, shares fell due to cash burn and lack of p
SenesTech reported Q2 2026 earnings with revenue up 23.2% to $770,000, surpassing analyst estimates. Diluted EPS narrowed to -$0.35, alongside notable insider stock purchases.
SenesTech reported Q2 2026 revenue up 23% to $770,000 driven by e-commerce, though net losses widened due to higher expenses. The company aims for profitability through sustained online growth and bet
SenesTech Inc reported record Q2 2026 revenue of $770,000, rising 56% sequentially, driven by e-commerce and agricultural B2B growth. Gross margins hit a record 73.6%.
SenesTech Inc. launched new assessment services for B2B clients to analyze rodent infestations and guide long-term management strategies. The offerings complement existing solutions like fertility con
SenesTech Inc will report Q2 2026 earnings on August 5, with estimated revenue of $0.6 million. GuruFocus forecasts a 74% downside despite analyst targets suggesting upside.
SenesTech reported a 186% surge in e-commerce revenue during Q2 2026, driven by doubling online subscription customers. The growth supports their subscription model for Evolve and ContraPest rodent bi
SenesTech reported its active online subscription customer base doubled in Q2 2026, with e-commerce revenue surging 186% driven by digital marketing and sales channel management for its Evolve and Con
SenesTech Inc. announced its active online subscription base more than doubled in Q2 2026 versus Q1, fueled by e-commerce investments. This growth strengthens their recurring revenue model for rodent
SenesTech reported its active online subscriptions more than doubled in Q2 2026, driving an 186% quarter-over-quarter e-commerce growth. This supports recurring revenue for its Evolve and ContraPest r
SenesTech Inc. will announce its Q2 2026 financial results after market close on August 5, 2026, with a concurrent conference call and webcast available via its Investor Relations website.
SenesTech Inc ranks 58th out of 65 in the Chemicals industry with a risk score of 2.26. The company exhibits lower volatility than the S&P 500 with a beta of 0.28.
ChemBrief